IMMX

Immix Biopharma, Inc. IMMX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-11.56M

Quarter to Jun 30

Free cash flow

$-11.76M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$579.55M total
Jupiter Topco LLC
$100.82M--
Saturn V Capital Management LP
$48.03M+26.1%
EVENTIDE ASSET MANAGEMENT, LLC
$40.12M+52.6%
STATE STREET CORP
$30.90M+1461.6%
BlackRock, Inc.
$30.83M+538.4%
Deep Track Capital, LP
$28.61MNew
VANGUARD CAPITAL MANAGEMENT LLC
$25.85M+40.2%
Opaleye Management Inc.
$24.18MNew
MILLENNIUM MANAGEMENT LLC
$21.30M+18.1%
UBS Group AG
$20.02M+2427.4%
MARSHALL WACE, LLP
$18.51M+9.3%
PRICE T ROWE ASSOCIATES INC /MD/
$17.94M+319.3%
WELLINGTON MANAGEMENT GROUP LLP
$15.19MNew
GREAT POINT PARTNERS LLC
$13.17M+265.0%
GEODE CAPITAL MANAGEMENT, LLC
$12.39M+159.2%
Velan Capital Investment Management LP
$11.19M+46.6%
Bleichroeder LP
$10.31M0.0%
Logos Global Management LP
$10.31M-18.4%
FRANKLIN RESOURCES INC
$9.99M0.0%
Burkehill Global Management, LP
$5.61M+85.0%
AMERIPRISE FINANCIAL INC
$5.35MNew
CITADEL ADVISORS LLC
$5.22M+973.0%
Blue Owl Capital Holdings LP
$4.51M-20.1%
NORTHERN TRUST CORP
$4.31M+202.4%
BALYASNY ASSET MANAGEMENT L.P.
$4.30MNew
See all 109 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/IMMX

Earnings Per Share

13fpro.ai/company/IMMX

Loading ratio trend…

IMMX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Immix Biopharma, Inc. (IMMX): stock profile, AI score and financials

Immix Biopharma, Inc. (IMMX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. IMMX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Immix Biopharma, Inc. reports net income of $-11.6M, free cash flow of $-11.8M. Top institutional holders of IMMX by reported 13-F value include Jupiter Topco, Saturn V Capital Management, EVENTIDE ASSET MANAGEMENT, based on the most recent SEC filings. IMMX trades on the Nasdaq exchange and files with the SEC under CIK 1873835. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMMX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Immix Biopharma, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1873835 →